ReviewActa pharmaceutica Sinica. B2020
Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment.
Review in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 71 citations in OpenAlex.
- The "Cold Tumor" to "Hot Tumor" transformation strategy for triple-negative breast cancer: from mechanism to clinical translation.Molecular and cellular biochemistry · 2026Review
- Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy.Cancer communications (London, England) · 2026Review
- Targeting Tumour Heterogeneity through sequential timing of anti-hallmark combination therapies -a hypothesis for implementation.Frontiers in immunology · 2026Review
- Vascular Disruption Therapy as a New Strategy for Cancer Treatment.International journal of molecular sciences · 2025Review
- The Duality of Collagens in Metastases of Solid Tumors.International journal of molecular sciences · 2025Review
- Angiogenesis in rheumatoid Arthritis: Pathological characterization, pathogenic mechanisms, and nano-targeted therapeutic strategies.Bioactive materials · 2025Review
- A novel angiogenesis-associated risk score predicts prognosis and characterizes the tumor microenvironment in colon cancer.Translational cancer research · 2024Article
- Self-assembled and perfusable microvasculature-on-chip for modeling leukocyte trafficking.Lab on a chip · 2024Article
- Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy-A Translational Model.Vaccines · 2023Article
- Cancer-associated inflammation: pathophysiology and clinical significance.Journal of cancer research and clinical oncology · 2023Review
- Intelligent nanotherapeutic strategies for the delivery of CRISPR system.Acta pharmaceutica Sinica. B · 2023Review
- Fundamental concepts of protein therapeutics and spacing in oncology: an updated comprehensive review.Medical oncology (Northwood, London, England) · 2023Review
- Engineered Vasculature for Cancer Research and Regenerative Medicine.Micromachines · 2023Review
- Challenges and exploration for immunotherapies targeting cold colorectal cancer.World journal of gastrointestinal oncology · 2023Review
- Microphysiological systems for solid tumor immunotherapy: opportunities and challenges.Microsystems & nanoengineering · 2023Review
- Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy.Acta pharmaceutica Sinica. B · 2022Review
- Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process.European journal of medical research · 2022Review
- The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma.Biomedicines · 2022Review
- Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor vasculature is characterized by aberrant structure and function, resulting in immune suppressive profiles of tumor microenvironment through limiting immune cell infiltration into tumors, endogenous immune surveillance and immune cell function. Vascular normalization as a novel therapeutic strategy tends to prune some of the immature blood vessels and fortify the structure and function of the remaining vessels, thus improving immune stimulation and the efficacy of immunotherapy. Interestingly, the presence of "immune‒vascular crosstalk" enables the formation of a positive feedback loop between vascular normalization and immune reprogramming, providing the possibility to develop new cancer therapeutic strategies. The applications of nanomedicine in vascular-targeting therapy in cancer have gained increasing attention due to its specific physical and chemical properties. Here, we reviewed the recent advances of effective routes, especially nanomedicine, for normalizing tumor vasculature. We also summarized the development of enhancing nanoparticle-based anticancer drug delivery
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.